- Home
- AVBH vs STTK Comparison
AVBH vs STTK Comparison
Compare AVBH & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVBH | STTK |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.4M | 275.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AVBH | STTK |
|---|---|---|
| Price | $27.43 | $5.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $33.00 | $7.00 |
| AVG Volume (30 Days) | 68.7K | ★ 573.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $360.39 | N/A |
| Revenue Next Year | $11.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.95 | $0.69 |
| 52 Week High | $31.61 | $6.13 |
Technical Indicators
Market Signals| Indicator | AVBH | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 31.44 | 75.00 |
| Support Level | $26.93 | $1.85 |
| Resistance Level | $27.72 | N/A |
| Average True Range (ATR) | 0.79 | 0.37 |
| MACD | -0.30 | 0.21 |
| Stochastic Oscillator | 0.95 | 92.44 |
Price Performance
Historical ComparisonAbout AVBH Avidbank Holdings Inc.
Avidbank Holdings Inc is a full-service commercial bank. It offers various services such as commercial and industrial lending, venture lending, structured finance, asset-based lending, sponsor finance, real estate construction, and commercial real estate lending.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.